 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Cnpair Biotech Co., Ltd. |
| Street 1: | Room C102, No. 509, Hongfeng Road, Yuhang District |
| Street 2: | |
| City: | Hangzhou |
| Province: | Zhejiang |
| Post Code: | 311100 |
| Country: | China |
| Phone: | ?+86 (571) 8831 2485? |
| Organization Email: | haifeng.luo@cnpair.com |
| Web Site: | http://www.cnpair.com/en/ |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 91330110MA28W1E8XE |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| Cnpair is a professional IVD raw materials provider in China. We, Cnpair personnel, are dedicated to developing and delivering highly competitive raw materials for IVD assay development and research applications. Cnpair was founded with the R&D and manufacturing facilities in Hangzhou, and sale offices in Shanghai, Hangzhou and Xiamen. The core staff have rich research and development experience on the IVD raw materials, IVD assays and related fields. Cnpair develops, produces and markets Antibodies, recombinant Antigens, native Antigens and Enzymes for IVD industry, especially immunoassay manufacturer. The products can be used for diagnosis on many markers, such as Infectious Diseases (HIV, HBV, HCV, TP, Influenza, TB, etc.), Tumor Markers, Cardiac Markers, Inflammation and Hormone. We provide raw materials extensively used in China, including HIV antigens, HIV p24 antibodies, TP antigens, TB stimulating antigens and anti-interferon-gamma antibodies, PCT antibodies, CRP antibodies, Influenza A NP antibodies and Influenza B NP antibodies … |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 26 - 50 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Attendance at a TB related event |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We provide the innovative recombinant protein and antibodies, and cooperate with diagnosis manufacturers to develop new kits, in order to contribute to TB control plan. | |
Geographical Reach | |
| Which country is your headquarters located in: | China |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB-HIV: We are developing the antibodies to TB-LAM, and will provide them to the industry to develop the cheap and effective diagnosis to the countries which need help to control TB-HIV. New Diagnostics: We provide the innovative protein and antibodies to develop and manufacture TB antibody detection kit and TB-IGRA kit. Research: We are working on the innovative diagnosis kit for TB detection, including TB-IGRA, TB-LAM detection kit. |
|
Declaration | |
| Declaration of interests: No conflict of interests. | |
| Application date: | March 8, 2020 |
| Last updated: | March 8, 2020 |